相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Presynaptic adenosine receptor heteromers as key modulators of glutamatergic and dopaminergic neurotransmission in the striatum
Sergi Ferre et al.
NEUROPHARMACOLOGY (2023)
The role of adenosine receptor ligands on inflammatory pain: possible modulation of TRPV1 receptor function
Mansour Haddad et al.
INFLAMMOPHARMACOLOGY (2023)
Adenosinergic Pathway in Parkinson's Disease: Recent Advances and Therapeutic Perspective
Yuan Zhao et al.
MOLECULAR NEUROBIOLOGY (2023)
Serotonin 5-HT1A receptors and their interactions with adenosine A2A receptors in Parkinson's disease and dyskinesia
Annalisa Pinna et al.
NEUROPHARMACOLOGY (2023)
The Multifaceted Role of GPCRs in Amyotrophic Lateral Sclerosis: A New Therapeutic Perspective?
Davide Bassani et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice
Sonia Burgaz et al.
MOLECULAR AND CELLULAR NEUROSCIENCE (2021)
Preclinical Investigation in Neuroprotective Effects of the GPR55 Ligand VCE-006.1 in Experimental Models of Parkinson's Disease and Amyotrophic Lateral Sclerosis
Sonia Burgaz et al.
MOLECULES (2021)
Glitazones Activate PGC-1α Signaling via PPAR-γ: A Promising Strategy for Antiparkinsonism Therapeutics
P. Prabitha et al.
ACS CHEMICAL NEUROSCIENCE (2021)
Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease
Isabel Espadas et al.
NEUROBIOLOGY OF DISEASE (2020)
The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomes
Javier Fernandez-Ruiz
BRITISH JOURNAL OF PHARMACOLOGY (2019)
Cannabinoid receptor as a potential therapeutic target for Parkinson's Disease
Himadri Shekhaar Baul et al.
BRAIN RESEARCH BULLETIN (2019)
Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration
Jose Aguareles et al.
TRANSLATIONAL NEURODEGENERATION (2019)
Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson's Disease
Sonia Burgaz et al.
MOLECULES (2019)
β-Caryophyllene (BCP) ameliorates MPP plus induced cytotoxicity
Guifang Wang et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
In Vitro Model of Neuroinflammation: Efficacy of Cannabigerol, a Non-Psychoactive Cannabinoid
Agnese Gugliandolo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: possible involvement of different binding sites at the PPARγ receptor
Concepcion Garcia et al.
JOURNAL OF NEUROINFLAMMATION (2018)
Combination Treatment of Icariin and L-DOPA Against 6-OHDA-Lesioned Dopamine Neurotoxicity
Di-Sheng Lu et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2018)
GPR55: A therapeutic target for Parkinson's disease?
Marta Celorrio et al.
NEUROPHARMACOLOGY (2017)
Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson's disease
Yolanda Gomez-Galvez et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2016)
VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease
Javier Diaz-Alonso et al.
SCIENTIFIC REPORTS (2016)
Cannabinoid Type 2 (CB2) Receptors Activation Protects against Oxidative Stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone Model of Parkinson's Disease
Hayate Javed et al.
FRONTIERS IN NEUROSCIENCE (2016)
Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications
Javier Fernandez-Ruiz et al.
NEUROTHERAPEUTICS (2015)
L-DOPA disrupts adenosine A2A-cannabinoid CB1-dopamine D2 receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: Biochemical and behavioral studies
Annalisa Pinna et al.
EXPERIMENTAL NEUROLOGY (2014)
A Cannabigerol Quinone Alleviates Neuroinflammation in a Chronic Model of Multiple Sclerosis
Aitor G. Granja et al.
JOURNAL OF NEUROIMMUNE PHARMACOLOGY (2012)
Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ9-THCV in animal models of Parkinson's disease
C. Garcia et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Cannabinoid Receptor Type 1 Protects Nigrostriatal Dopaminergic Neurons against MPTP Neurotoxicity by Inhibiting Microglial Activation
Young C. Chung et al.
JOURNAL OF IMMUNOLOGY (2011)
Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors
Sandra Perez-Rial et al.
NEUROBIOLOGY OF AGING (2011)
The CB1 antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease
J. E. Kelsey et al.
BEHAVIOURAL BRAIN RESEARCH (2009)
Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and α-synuclein-deleted mice
Daniel Alvarez-Fischer et al.
EXPERIMENTAL NEUROLOGY (2008)
Levodopa therapy from the neuroprotection viewpoint - From a clinical outlook
T Kondo
JOURNAL OF NEUROLOGY (2005)
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro:: Relevance to Parkinson's disease
I Lastres-Becker et al.
NEUROBIOLOGY OF DISEASE (2005)
A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function
M Lundblad et al.
NEUROBIOLOGY OF DISEASE (2004)
Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease
MA Cenci
AMINO ACIDS (2002)
分享论文
